HC Wainwright Has Bullish Forecast for FDMT FY2027 Earnings

Key Points

• HC Wainwright raised its FY2027 EPS forecast for 4D Molecular Therapeutics to a loss of $4.34 per share from $4.40 and maintained a Buy rating with a $36 price target. The broader analyst consensus is “Moderate Buy,” with an average target of $29.62.
• 4D Molecular Therapeutics reported a quarterly loss of $1.04 per share, slightly missing the $1.02 consensus estimate, while revenue of $3.78 million exceeded expectations. The company remains unprofitable, with analysts projecting losses through FY2030.
• FDMT shares opened at $14.55 after rising 19.4%, near the company’s 12-month high, while institutional investors own approximately 99.27% of outstanding shares. Insiders sold about $2.24 million of stock over the past 90 days, adding a potential negative signal for investors.

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) - Equities research analysts at HC Wainwright increased their FY2027 EPS estimates for shares of 4D Molecular Therapeutics in a report issued on Friday, August 14th. HC Wainwright analyst M. Caufield now forecasts that the company will post earnings of ($4.34) per share for the year, up from their prior forecast of ($4.40). HC Wainwright has a "Buy" rating and a $36.00 price objective on the stock. The consensus estimate for 4D Molecular Therapeutics' current full-year earnings is ($3.88) per share. HC Wainwright also issued estimates for 4D Molecular Therapeutics' FY2028 earnings at ($4.12) EPS, FY2029 earnings at ($2.72) EPS and FY2030 earnings at ($1.52) EPS.

Several other brokerages have also commented on FDMT. Weiss Ratings reiterated a "sell (d-)" rating on shares of 4D Molecular Therapeutics in a research report on Friday, July 17th. Wall Street Zen cut shares of 4D Molecular Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, May 9th. The Goldman Sachs Group restated a "buy" rating and issued a $32.00 price objective on shares of 4D Molecular Therapeutics in a report on Thursday. Chardan Capital raised shares of 4D Molecular Therapeutics to a "strong-buy" rating in a research note on Tuesday, July 28th. Finally, B. Riley Financial reaffirmed a "buy" rating on shares of 4D Molecular Therapeutics in a report on Monday. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $29.62.

4D Molecular Therapeutics Trading Up 19.4%

NASDAQ FDMT opened at $14.55 on Tuesday. The company has a quick ratio of 8.03, a current ratio of 8.03 and a debt-to-equity ratio of 0.05. The stock's 50-day simple moving average is $11.06 and its two-hundred day simple moving average is $9.93. 4D Molecular Therapeutics has a twelve month low of $5.97 and a twelve month high of $15.03. The company has a market capitalization of $760.67 million, a price-to-earnings ratio of -5.53 and a beta of 2.73.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.02). The company had revenue of $3.78 million for the quarter, compared to the consensus estimate of $3.62 million. 4D Molecular Therapeutics had a negative return on equity of 41.33% and a negative net margin of 194.74%.

Insider Buying and Selling

In related news, insider David Kirn sold 114,746 shares of 4D Molecular Therapeutics stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $10.47, for a total value of $1,201,390.62. Following the transaction, the insider directly owned 942,485 shares of the company's stock, valued at $9,867,817.95. The trade was a 10.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Scott Bizily sold 9,810 shares of the company's stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $12.00, for a total transaction of $117,720.00. Following the sale, the insider owned 8,617 shares of the company's stock, valued at $103,404. This represents a 53.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 200,496 shares of company stock worth $2,240,244 over the last ninety days. Insiders own 7.90% of the company's stock.

Hedge Funds Weigh In On 4D Molecular Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Jupiter Topco LLC purchased a new stake in shares of 4D Molecular Therapeutics during the second quarter worth about $76,466,000. BlackRock Inc. purchased a new position in 4D Molecular Therapeutics during the 2nd quarter valued at about $60,463,000. Janus Henderson Group PLC raised its position in 4D Molecular Therapeutics by 164.4% during the 4th quarter. Janus Henderson Group PLC now owns 4,635,875 shares of the company's stock valued at $34,726,000 after purchasing an additional 2,882,508 shares during the last quarter. Trails Edge Capital Partners LP bought a new stake in shares of 4D Molecular Therapeutics in the 2nd quarter worth approximately $29,631,296,000. Finally, State Street Corp increased its stake in shares of 4D Molecular Therapeutics by 197.5% during the fourth quarter. State Street Corp now owns 2,688,880 shares of the company's stock valued at $20,167,000 after buying an additional 1,785,106 shares during the period. 99.27% of the stock is owned by institutional investors.

Trending Headlines about 4D Molecular Therapeutics

Here are the key news stories impacting 4D Molecular Therapeutics this week:

• Positive Sentiment: Analysts remain constructive: HC Wainwright reiterated a Buy rating with a $36 price target, while the broader analyst consensus is “Moderate Buy” with an average target of $29.62. Goldman Sachs also maintained a Buy rating and a $32 target. These targets imply substantial potential upside from recent trading levels. Analyst ratings and price targets
• Positive Sentiment: Institutional interest has strengthened, with Bank of America, Man Group, Jupiter Topco and other investors establishing positions during the second quarter. Institutions collectively own approximately 99.27% of FDMT’s outstanding shares, signaling strong professional-investor participation. Institutional investment and stock performance article
• Positive Sentiment: FDMT recently reached a new 12-month high, with its market momentum supported by a share price well above its 50-day and 200-day moving averages. 4D Molecular Therapeutics reaches 12-month high
• Neutral Sentiment: HC Wainwright’s earnings revisions were mixed: its FY2027 loss estimate improved modestly to $4.34 per share from $4.40, but projected losses for FY2028 through FY2030 widened slightly. The revisions indicate a longer path to profitability despite the firm’s bullish rating.
• Negative Sentiment: Insider Scott Bizily sold 1,635 shares for approximately $19,620 at an average price of $12.00, reducing his direct holdings by 15.95%. A separate filing also reported a comparable sale at $12.20. Repeated insider selling may weigh on sentiment, although the transactions are relatively small. 4D Molecular Therapeutics insider sale
• Negative Sentiment: 4D Molecular Therapeutics recently reported a quarterly loss of $1.04 per share, slightly worse than the $1.02 analyst consensus. Revenue of $3.78 million modestly exceeded estimates, but the company’s negative net margin and projected full-year loss of $3.88 per share underscore ongoing profitability and execution risks.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D's pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source